Advanced Design of a Nicotine Vaccine for Smoking Cessation

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$352,841.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43DA033845-01
Agency Tracking Number:
R43DA033845
Solicitation Year:
2012
Solicitation Topic Code:
NIDA
Solicitation Number:
PA10-123
Small Business Information
TRIA BIOSCIENCE CORPORATION
1616 Eastlake Ave E Ste 260, SEATTLE, WA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
831016907
Principal Investigator:
CHRISTOPHER CLEGG
(206) 819-9413
cclegg@triabio.com
Business Contact:
MARCIA TAPP
(206) 826-7954
mtapp@triabio.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Tobacco smoke is the primary cause of lung cancer, cardiovascular disease and premature death, with nearly 5 million people dying each year. Treatments that prevent smoking will have a major impact on global health andare attractive products for commercial development. Nicotine vaccines and antibodies represent an important strategy for preventing nicotine from reaching the brain, although current clinical-stage vaccines are ineffective and for most people the antibodyresponse is weak and short-lived. The challenge of inducing long- lasting antibodies titers requires a better method for presenting nicotine to the immune system. We hypothesize that targeted nicotine delivery to dendritic cells using agonistic mAbs to CD40 combined with a TLR4-based adjuvant will stimulate a superior antibody response. We will modify the rat anti-mouse CD40 mAb 1C10 for studies in mice and optimize its conjugation with derivatized nicotine. Mice will be vaccinated with ?CD40nic formulatedwith the TLR4-activating adjuvant GLA-SE. Anti-nicotine antibody titers will be benchmarked against mice vaccinated with a traditional vaccine, nicotine-KLH + alum. Vaccine potency will be determined using quantitative measures of antibody function including nicotine sequestration in blood and prevention of a nicotine abstinence response. Phase I SBIR funding will establish proof-of-concept in a relevant model and provide the justification for subsequent IND-enabling studies that will bring an innovative vaccine for smoking cessation into the clinic. PUBLIC HEALTH RELEVANCE: Tobacco smoke is the primary cause of lung cancer, cardiovascular disease and premature death. There is a strong unmet need for an effective aid to smoking cessation. To halt the addictive effects of nicotine and increase the success rate for smoking cessation, we have designed a novel vaccine that will prevent nicotine from crossing the blood-brain barrier.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government